Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar

Kavanaugh, A, Matucci-Cerinic, M, Schulze-Koops, H et al. (4 more authors) (2018) Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Metadata

Authors/Creators:
Dates:
  • Published: September 2018
  • Accepted: 16 August 2018
  • Published (online): 15 October 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 16 Apr 2019 16:01
Last Modified: 16 Apr 2019 16:01
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/art.40700
Related URLs:

Share / Export

Statistics